Development and validation of a respiratory syncytial virus multiplex immunoassay
© 2024. The Author(s)..
PURPOSE: Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. While vaccines and monoclonal therapeutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses antibody titers toward the post-F, Nucleoprotein, and a diverse mix of G proteins.
METHODS: A bead-based multiplex RSV immunoassay was developed, technically validated to standard FDA bioanalytical guidelines, and clinically validated using samples from human challenge studies. RSV antibody titers were then investigated in children aged under 2 and a population-based cohort.
RESULTS: Technical and clinical validation showed outstanding performance, while methodological developments enabled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody responses within population cohorts.
CONCLUSION: Overall, the developed assay shows robust performance, is scalable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Infection - 52(2024), 2 vom: 07. März, Seite 597-609 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marsall, Patrick [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 21.03.2024 Date Revised 23.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s15010-024-02180-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368217418 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368217418 | ||
| 003 | DE-627 | ||
| 005 | 20240323235035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-024-02180-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM368217418 | ||
| 035 | |a (NLM)38332255 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marsall, Patrick |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and validation of a respiratory syncytial virus multiplex immunoassay |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. While vaccines and monoclonal therapeutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses antibody titers toward the post-F, Nucleoprotein, and a diverse mix of G proteins | ||
| 520 | |a METHODS: A bead-based multiplex RSV immunoassay was developed, technically validated to standard FDA bioanalytical guidelines, and clinically validated using samples from human challenge studies. RSV antibody titers were then investigated in children aged under 2 and a population-based cohort | ||
| 520 | |a RESULTS: Technical and clinical validation showed outstanding performance, while methodological developments enabled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody responses within population cohorts | ||
| 520 | |a CONCLUSION: Overall, the developed assay shows robust performance, is scalable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibody | |
| 650 | 4 | |a Multiplex | |
| 650 | 4 | |a RSV | |
| 650 | 4 | |a Serosurveillance | |
| 650 | 7 | |a Viral Fusion Proteins |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a GTP-Binding Proteins |2 NLM | |
| 650 | 7 | |a EC 3.6.1.- |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Fandrich, Madeleine |e verfasserin |4 aut | |
| 700 | 1 | |a Griesbaum, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Harries, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Berit |e verfasserin |4 aut | |
| 700 | 0 | |a RESPINOW Study Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Ascough, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Dayananda, Pete |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Remppis, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Ganzenmueller, Tina |e verfasserin |4 aut | |
| 700 | 1 | |a Renk, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Strengert, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Schneiderhan-Marra, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Dulovic, Alex |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d 1973 |g 52(2024), 2 vom: 07. März, Seite 597-609 |w (DE-627)NLM00001740X |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2024 |g number:2 |g day:07 |g month:03 |g pages:597-609 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s15010-024-02180-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2024 |e 2 |b 07 |c 03 |h 597-609 | ||